CTRI/2018/05/013591尚未招募未知
Assessment of safety & efficacy of Bromocriptine in comparison with Teneligliptin in newly diagnosed type II diabetes mellitus
asrin Nisha0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Newly diagnosed type 2 DM
- •FBS between 140 mg/dl and 240 mg/dl
- •PPBS between 200 mg/dl and 350 mg/dl
- •Hb1Ac between 7% &10%
- •BMI between 22 and 40 kg/m2
排除标准
- •Patients with complications of DM
- •Pregnant & nursing women
- •Patients with known hypersensitivity to Bromocriptine or ergot related compounds or Teneligliptin.
- •Patients with migraine.
- •Patients with H/O significant systemic disorders
研究者
相似试验
招募中
2 期
Role of bromocriptine through enteral route for decreasing neurogenic fever in severe head Injury patients in Trauma Intensive Care Unit.CTRI/2023/08/056344Institute of medical sciences Banaras hindu university
Unknown
3 期
Comparison of Effect of Bromocriptine mesylate and Pioglitazone in uncontrolled type 2 Diabetic PatientsCTRI/2011/12/002306Smt Kashibai Navale Medical College and Hospital60
进行中（未招募）
不适用
Überwachung einer Therapie mit Bromocriptin bei Patienten mit klinisch relevanter Risperidon-induzierter Hyperprolaktinämie. Eine psychiatrisch-endokrinologische Ver-laufsbeobachtung.Schizophrene Patienten mit einer Risperidon induzierten HyperprolaktinämieEUCTR2005-006037-33-DEniversitätsklinikum Bonn; Klinik und Poliklinik für Psychiatrie und Psychotherapie
已完成
不适用
Bromocriptin and rheumatoid arthritisRheumatoid arthritis.Seropositive rheumatoid arthritisIRCT201008121778N3Vice chancellor of research, Isfahan University of Medical Sciences80
招募中
2 期
Role of Bromocriptine in patients with difficulty in speech following strokeCTRI/2013/04/003539Dr Reeba Sini Jacob88